FrancophonIA/ELRC3.0 huggingface dataset:
English: Hypoglycaemia (when used with sulphonylurea or insulin) Thirst
Croatian: Hipoglikemija (kada je primjenjivan sa sulfonilurejom ili inzulinom) Žeđ
English: What Glyxambi is and what it is used for What you need to know before you take Glyxambi How to take Glyxambi
Croatian: Što je Glyxambi i za što se koristi Što morate znati prije nego počnete uzimati Glyxambi
English: Pyelonephritis and urosepsis were not reported from the clinical trials in patients treated with Glyxambi.
Croatian: Pijelonefritis i urosepsa nisu bili prijavljeni u kliničkim ispitivanjima u bolesnika liječenih lijekom Glyxambi.
English: Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms.
Croatian: Na temelju in vitro ispitivanja empagliflozin ne inhibira, ne inaktivira niti ne inducira izoforme CYP450.
English: Simulations of steady-state plasma concentrations of linagliptin with and without ritonavir indicated that the increase in exposure will be not associated with an increased accumulation.
Croatian: Simulacije koncentracija linagliptina u plazmi u stanju dinamičke ravnoteže, sa ili bez ritonavira, ukazale su na to da povećanje u izloženosti neće biti povezano s povećanom akumulacijom.
English: The majority of drug-related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug related radioactivity excreted in urine was unchanged parent drug.
Croatian: Većina radioaktivnosti povezane s lijekom, koja je pronađena u fecesu, bio je nepromijenjeni ishodišni lijek, a približno polovica radioaktivnosti povezane s lijekom, koja se izlučila mokraćom, bila je nepromijenjeni ishodišni lijek.
English: Major hypoglycaemia with empagliflozin (events requiring assistance)
Croatian: Teška hipoglikemija tijekom primjene empagliflozina (događaji koji zahtijevaju asistenciju)
English: Overall, the safety profile of Glyxambi was in line with the safety profiles of the individual active substances (empagliflozin and linagliptin).
Croatian: Sveukupno, sigurnosni profil lijeka Glyxambi bio je u skladu sa sigurnosnim profilima pojedinačnih djelatnih tvari (empagliflozina i linagliptina).
English: The intra-subject and inter-subject coefficients of variation for linagliptin AUC were small (12.6 % and 28.5 %, respectively).
Croatian: Koeficijenti varijacije u istog ispitanika i između ispitanika za AUC linagliptina bili su niski (12,6%, odnosno 28,5%).
English: Glyxambi is not recommended and your doctor may decide to use an alternative medicine.
Croatian: Glyxambi se tada ne preporučuje, a liječnik se može odlučiti za primjenu drugog lijeka.
English: Insulin and sulphonylureas
Croatian: Inzulin i sulfonilureje
English: Type 2 diabetes is a condition that comes from both your genes and your lifestyle.
Croatian: Šećerna bolest tipa 2 je stanje za koje su odgovorni kako geni tako i način života.
English: Therapeutic experience is limited with Glyxambi in patients > 75 years of age, and, no experience is available in patients aged 85 years and older.
Croatian: Terapijsko iskustvo s lijekom Glyxambi u bolesnika u dobi od 75 i više godina je ograničeno, a ne postoji iskustvo u bolesnika u dobi od 85 i više godina.
English: Increased urinary glucose excretion was maintained at the end of the 4-week treatment period, averaging approximately 78 g/day.
Croatian: Povećano izlučivanje glukoze u mokraći održalo se na kraju 4-tjednog razdoblja liječenja iznoseći u prosjeku približno 78 g/dan.
English: However, caution is advised when Glyxambi is used in combination with antidiabetics.
Croatian: Međutim, savjetuje se oprez kada se primjenjuje Glyxambi u kombinaciji s antidijabeticima.
English: In a clinical trial with empagliflozin, haematocrit values returned towards baseline values after a follow-up period of 30 days after treatment stop.
Croatian: U kliničkom ispitivanju s empagliflozinom vrijednosti hematokrita su se vratile na početne vrijednosti nakon razdoblja praćenja od 30 dana nakon prekida liječenja.
English: The glucosuria observed with empagliflozin is accompanied by diuresis which may contribute to sustained and moderate reduction of blood pressure.
Croatian: Glukozurija, koja je opažena s empagliflozinom, bila je praćena diurezom, koja može doprinijeti trajnom i umjerenom snižavanju krvnog tlaka.
English: Experience with empagliflozin in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with empagliflozin in NYHA class III-IV.
Croatian: Iskustvo u liječenju empagliflozinom bolesnika klase I-II prema klasifikaciji NYHA (New York Heart Association) je ograničeno, a ne postoje iskustva iz kliničkih ispitivanja primjene empagliflozina u bolesnika klase III-IV prema NYHA klasifikaciji.
English: Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2.
Croatian: Empagliflozin je reverzibilni, visoko potentni (IC50 iznosi 1,3 nmol) i selektivni kompetitivni SGLT2 inhibitor.
English: C]-empagliflozin solution to healthy volunteers, the red blood cell partitioning was approximately 37 % and plasma protein binding was
Croatian: C]-empagliflozina u zdravih dobrovoljaca, raspodjela u crvene krvne stanice je iznosila približno 37%, a vezanje na proteine plazme 86%.
English: (See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied)
Croatian: (za dostupne podatke o ispitivanim kombinacijama vidjeti dijelove 4.2, 4.4, 4.5 i 5.1)
English: Consistent with the half life, up to 22 % accumulation, with respect to plasma AUC, was observed at steady state.
Croatian: Konzistentno s poluvijekom, opažena je akumulacija do 22% u odnosu na plazmatski AUC pri stanju dinamičke ravnoteže.
English: The unbound concentrations, which are usually less than 1 % at the therapeutic dose of linagliptin, were increased 4 to 5-fold after co-administration with ritonavir.
Croatian: Koncentracije nevezane frakcije lijeka, koje su obično niže od 1% pri terapijskoj dozi linagliptina, povećale su se 4 do 5 puta nakon istodobne primjene s ritonavirom.
English: As a precautionary measure it is preferable to avoid the use of Glyxambi during pregnancy.
Croatian: Kao mjera opreza, preporučuje se izbjegavati primjenu lijeka Glyxambi tijekom trudnoće.
English: Based on very limited experience in patients 75 years and older, initiation of Glyxambi therapy is not recommended in this population (see sections 4.4 and 5.2).
Croatian: Na temelju vrlo ograničenog iskustva u bolesnika u dobi od 75 i više godina ne preporučuje se započinjanje terapije lijekom Glyxambi u ovoj populaciji (vidjeti dijelove 4.4 i 5.2).
English: At baseline, 74 % of patients were being treated with metformin, 48 % with insulin, and 43 % with a sulfonylurea.
Croatian: Na početku ispitivanja, 74% bolesnika je bilo liječeno metforminom, 48% inzulinom, a 43% sulfonilurejom.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Glyxambi in all subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Glyxambi u svim podskupinama pedijatrijske populacije sa šećernom bolešću tipa 2 (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD19
Croatian: Farmakoterapijska skupina: Lijekovi za liječenje šećerne bolesti, kombinacije oralnih lijekova za snižavanje glukoze u krvi, ATK oznaka: A10BD19
English: Animal studies with empagliflozin have shown adverse effects on postnatal development (see section 5.3).
Croatian: Ispitivanja empagliflozina na životinjama su pokazala štetne učinke na postnatalni razvoj (vidjeti dio 5.3).
English: Glyxambi can therefore be taken with or without food.
Croatian: Glyxambi se stoga može uzeti sa ili bez hrane.
English: The effects of Glyxambi on pregnancy, breast-feeding and fertility are not known.
Croatian: Nisu poznati učinci lijeka Glyxambi na trudnoću, dojenje i plodnost.
English: Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours) that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the medicinal product.
Croatian: Koncentracije linagliptina u plazmi padaju na trifazičan način, s dugačkim terminalnim poluvijekom (terminalni poluvijek linagliptina više od 100 sati), što je uglavnom povezano sa saturabilnim, čvrstim vezanjem linagliptina na DPP-4 te ne pridonosi akumulaciji lijeka.
English: By blocking this protein, the medicine causes glucose (blood sugar), sodium (salt) and water to be removed via the urine.
Croatian: Blokiranjem tog proteina ovaj lijek uzrokuje izlučivanje glukoze (šećer u krvi), natrija (soli) i vode putem mokraće.
English: During controlled clinical trials in healthy subjects, single doses of up to 600 mg linagliptin (equivalent to 120 times the recommended dose) were generally well tolerated.
Croatian: Tijekom kontroliranih kliničkih ispitivanja na zdravim ispitanicima, jednostruke doze do 600 mg linagliptina (što odgovara 120 puta višim dozama od preporučenih) su bile općenito dobro podnošene.
English: Your blood sugar levels may increase when you stop taking Glyxambi.
Croatian: Razina šećera u krvi se može povećati ako prestanete s uzimanjem lijeka Glyxambi.
English: Co-administration with other potent inducers of P-gp and CYP3A4, such as carbamazepine, phenobarbital and phenytoin, has not been studied.
Croatian: Istodobna primjena s drugim snažnim induktorima P-gp-a i CYP3A4, kao što su karbamazepin, fenobarbital i fenitoin, nije ispitivana.
English: The most frequently reported adverse event in clinical trials with linagliptin was hypoglycaemia observed under the triple combination, linagliptin plus metformin plus sulphonylurea (22.9 % vs 14.8 % in placebo).
Croatian: Najčešće prijavljeni štetni događaj u kliničkim ispitivanjima linagliptina bila je hipoglikemija, primijećena u trojnoj kombinaciji, linagliptin plus metformin plus sulfonilureja (22,9% naspram 14,8% uz placebo).
English: Glyxambi should not be used for the treatment of diabetic ketoacidosis.
Croatian: Glyxambi se ne smije primjenjivati u liječenju dijabetičke ketoacidoze.
English: One main metabolite with a relative exposure of 13.3 % of linagliptin at steady-state was detected which was found to be pharmacologically inactive and thus to not contribute to the plasma DPP-4 inhibitory activity of linagliptin.
Croatian: Pronađen je jedan glavni metabolit s relativnom izloženosti od 13,3% linagliptina u stanju dinamičke ravnoteže, za koji je otkriveno da je farmakološki neaktivan te stoga ne pridonosi DPP-4-inhibicijskoj aktivnosti linagliptina u plazmi.
English: The reduction of cardiovascular death was comparable for empagliflozin 10 mg and 25 mg and confirmed by an improved overall survival (see Table 5).
Croatian: Smanjenje kardiovaskularne smrti je bilo usporedivo za empagliflozin 10 mg i 25 mg te potvrđeno poboljšanim ukupnim preživljenjem (vidjeti tablicu 5).
English: If pancreatitis is suspected, Glyxambi should be discontinued; if acute pancreatitis is confirmed, Glyxambi should not be restarted.
Croatian: Ako se sumnja na pankreatitis, potrebno je prekinuti primjenu lijeka Glyxambi; ako se akutni pankreatitis potvrdi, ne smije se ponovno započeti s primjenom lijeka Glyxambi.
English: If you take more Glyxambi than you should
Croatian: Ako uzmete više lijeka Glyxambi nego što ste trebali
English: The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration or sudden reductions in insulin dose, or following major surgery or serious illness that increases your need for insulin.
Croatian: Rizik od razvoja dijabetičke ketoacidoze može biti povećan kod produljenog gladovanja, prekomjerne konzumacije alkohola, dehidracije ili iznenadnog smanjenja doze inzulina, te nakon velikog kirurškog zahvata ili ozbiljne bolesti koja povećava Vašu potrebu za inzulinom.
English: Pancreatitis Mouth ulceration
Croatian: Pankreatitis Ulceracija usne šupljine
English: Allergic reactions, seen uncommonly (may affect up to 1 in 100 people) This medicine may cause allergic reactions, which may be serious, including hives (urticaria) and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing (angioedema).
Croatian: Alergijske reakcije, zabilježene manje često (mogu se javiti u do 1 na 100 osoba) Ovaj lijek može uzrokovati alergijske reakcije, koje mogu biti ozbiljne, uključujući koprivnjaču (urtikariju), i oticanje lica, usana, jezika i grla, što može izazvati teškoće s disanjem ili gutanjem (angioedem).
English: • Linagliptin works in a different way, namely by enabling the pancreas to produce more insulin to lower blood glucose levels.
Croatian: • Linagliptin djeluje na drugačiji način, tako što omogućava gušterači veću proizvodnju inzulina u cilju snižavanja razine glukoze u krvi.
English: C] linagliptin oral 10 mg dose, approximately 5 % of the radioactivity was excreted in urine.
Croatian: C]-linagliptina od 10 mg, oko 5% radioaktivnosti izlučilo se putem urina.
English: • if you are 75 years old or older, as increased passing of urine due to the medicine may affect fluid balance in your body and increase your risk of dehydration.For possible signs of dehydration, see section 4.
Croatian: • ako imate 75 ili više godina, jer pojačano izlučivanje mokraće uslijed djelovanja lijeka može utjecati na poremećaj ravnoteže tekućina u tijelu te povećati rizik od dehidracije.
English: Based on the population pharmacokinetic analysis, the apparent terminal elimination half life of empagliflozin was estimated to be 12.4 hours and apparent oral clearance was 10.6 L/hour.
Croatian: Na temelju farmakokinetičke analize populacije procijenjeno je da prividni terminalni poluvijek eliminacije empagliflozina iznosi 12,4 sati, a prividni oralni klirens je iznosio 10,6 l/sat.
English: For weight, baseline weight is also included.
Croatian: Za tjelesnu težinu također je uključena početna vrijednost tjelesne težine.
English: In clinical trials, nineteen patients 75 years or older were treated with Glyxambi.
Croatian: U kliničkim ispitivanjima devetnaest bolesnika u dobi od 75 godina i više bili su liječeni lijekom Glyxambi.
English: The population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased with a decrease in eGFR leading to an increase in drug exposure (see section 4.2).
Croatian: Farmakokinetička analiza populacije pokazala je da se prividni oralni klirens empagliflozina smanjio sa smanjenjem vrijednosti eGFR dovodeći do povećanja izloženosti lijeku (vidjeti dio 4.2).
English: Due to the concentration dependent binding of linagliptin to DPP-4, the pharmacokinetics of linagliptin based on total exposure is not linear; indeed total plasma AUC of linagliptin increased in a less than dose-proportional manner while unbound AUC increases in a roughly dose-proportional manner.
Croatian: Zbog vezanja linagliptina na DPP-4 ovisnog o koncentraciji, farmakokinetika linagliptina koja se temelji na ukupnoj izloženosti nije linearna; zapravo se ukupni AUC linagliptina u plazmi povećao na način manje od proporcionalno s dozom, dok se nevezani AUC povećao ugrubo proporcionalno s dozom.
English: Low blood sugar (hypoglycaemia), seen commonly (may affect up to 1 in 10 people) If you take Glyxambi with another medicine that can cause low blood sugar, such as a sulphonylurea or insulin, you are at risk of getting too low blood sugar (hypoglycaemia).
Croatian: Niska razina šećera u krvi (hipoglikemija), zabilježena često (može se javiti u do 1 na 10 osoba) Ako uzimate Glyxambi s drugim lijekom koji može izazvati nisku razinu šećera u krvi, poput sulfonilureje ili inzulina, postoji rizik od nastanka pretjerano niske razine šećera u krvi (hipoglikemije).
English: Hypoglycaemias in the placebo-controlled studies (10.9 %; N=471) were mild (80 %; N=384), moderate (16.6 %; N=78) or severe (1.9 %; N=9) in intensity.
Croatian: Hipoglikemija u placebom kontroliranim ispitivanjima (10,9%; N= 471) je bila blagog (80%; N= 384), umjerenog (16,6%; N= 78) ili jakog (1,9%; N= 9) intenziteta.
English: Improvement of surrogate markers of beta cell function including Homeostasis Model Assessment β (HOMA β) was noted.
Croatian: Zabilježeno je poboljšanje surogatnih biljega funkcije beta-stanica uključujući HOMA β (engl.
English: In patients with type 2 diabetes, urinary glucose excretion increased immediately following the first dose of empagliflozin and was continuous over the 24-hour dosing interval.
Croatian: U bolesnika sa šećernom bolešću tipa 2 izlučivanje glukoze mokraćom povećalo se neposredno nakon prve doze empagliflozina i bilo je kontinuirano tijekom 24-satnog intervala doziranja.
English: Taking this medicine in combination with sulphonylureas or insulin, can cause your blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and changes in vision, and may affect your ability to drive and use machines.
Croatian: Uzimanje ovog lijeka u kombinaciji sa sulfonilurejama ili inzulinom može dovesti do pretjerano niskih razina šećera u krvi (hipoglikemija), što može izazvati simptome poput drhtavice, znojenja i promjena vida, te može utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: PVC/PVDC/aluminium perforated unit dose blisters.
Croatian: PVC/PVDC/aluminij perforirani blisteri djeljivi na jedinične doze.
English: Your doctor may want to reduce your dose of these medicines when you take them together with Glyxambi, in order to avoid too low blood sugar (hypoglycaemia).
Croatian: Liječnik će Vam možda sniziti dozu tih lijekova ako ih uzimate zajedno s lijekom Glyxambi kako bi se izbjegla pretjerano snižena razina šećera u krvi (hipoglikemija).
English: Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection
Croatian: Vaginalna monilijaza, vulvovaginitis, balanitis i druge genitalne infekcije
English: Do not take Glyxambi: - if you are allergic to empagliflozin, linagliptin, any other SGLT2 inhibitor (e.g. dapagliflozin, canagliflozin), any other DPP-4 inhibitor (e.g. sitagliptin, vildagliptin), or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati Glyxambi: - ako ste alergični na empagliflozin, linagliptin ili bilo koji SGLT2 inhibitor (npr. dapagliflozin, kanagliflozin) ili DPP4-inhibitor (npr. sitagliptin, vildagliptin) ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
English: • When eGFR is persistently below 45 mL/min/1.73 m2 or CrCl persistently below 45 mL/min, treatment should be discontinued (see sections 4.4, 4.8, 5.1, and 5.2).
Croatian: • Kada je eGFR trajno ispod 45 ml/min/1,73 m 2 ili CrCl trajno ispod 45 ml/min, liječenje se mora prekinuti (vidjeti dijelove 4.4, 4.8, 5.1 i 5.2).
English: Based on the mode of action of SGLT2 inhibitors, osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure (see section 5.1).
Croatian: Na temelju načina djelovanja SGLT2 inhibitora, osmotska diureza, koja prati terapijsku glukozuriju, može dovesti do blagog sniženja krvnog tlaka (vidjeti dio 5.1).
English: • increased pancreas enzyme lipase
Croatian: • povišena razina gušteračnog enzima lipaze
English: Based on results of pharmacokinetic studies, no dose adjustment of Glyxambi is recommended when co-administered with commonly prescribed medicinal products, except those mentioned below.
Croatian: Na temelju rezultata farmakokinetičkih ispitivanja ne preporučuje se prilagođavanje doze lijeka Glyxambi pri istodobnoj primjeni s često propisivanim lijekovima, osim onih navedenih u nastavku.
English: Approximately 19 % of the population had an eGFR <60 mL/min/1.73 m
Croatian: Približno 19% populacije imalo je eGFR < 60 ml/min/1,73 m
English: If a dose is missed, and it is less than 12 hours until the next dose, the dose should be skipped and the next dose should be taken at the usual time.
Croatian: U slučaju propuštene doze, te ako do sljedeće doze ima manje od 12 sati, dozu je potrebno preskočiti, a sljedeću dozu uzeti u uobičajeno vrijeme.
English: Your doctor may ask you to stop taking Glyxambi until you recover, to prevent loss of too much body fluid.
Croatian: Vaš liječnik može zatražiti da prestanete uzimati Glyxambi sve dok se ne oporavite kako bi se spriječio preveliki gubitak tjelesne tekućine.
English: Co-administration of rifampicin decreased linagliptin exposure by 40 %, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-glycoprotein (P-gp) or cytochrome P450 (CYP) isozyme CYP3A4 inducer, particularly if these are administed long-term (see section 5.2).
Croatian: Istodobna primjena rifampicina je snizila izloženost linagliptinu za 40% sugerirajući da se djelotvornost linagliptina može smanjiti pri primjeni u kombinaciji sa snažnim induktorom P-glikoproteina (P-gp) ili citokrom P450 (CYP) izoenzima CYP3A4, naročito ako se oni dugoročno primjenjuju (vidjeti dio 5.2).
English: • if you are taking other anti-diabetic medicines known as “sulphonylurea” (e.g. glimepiride, glipizide) and/or insulin.
Croatian: • ako uzimate druge lijekove za liječenje šećerne bolesti poznate kao „sulfonilureje“ (npr. glimepirid, glipizid) i/ili inzulin.
English: The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food.
Croatian: Opaženi učinak hrane na farmakokinetiku empagliflozina nije se smatrao klinički značajnim te se empagliflozin može primjenjivati sa ili bez hrane.
English: SGLT2 prevents glucose from being excreted in urine by absorbing glucose back into the bloodstream as blood is being filtered in the kidneys.
Croatian: SGLT2 sprječava izlučivanje glukoze mokraćom tako što apsorbira glukozu nazad u krvotok dok se krv filtrira u bubrezima.
English: C] linagliptin dose to healthy subjects, approximately 85 % of the administered radioactivity was eliminated in faeces (80 %) or urine (5 %) within 4 days of dosing.
Croatian: C]-linagliptina u zdravih osoba, oko 85% primijenjene radioaktivnosti bilo je eliminirano putem fecesa (80%) ili urina (5%) unutar 4 dana od doziranja.
English: This helps to lower blood glucose levels, which are too high because of your type 2 diabetes.
Croatian: To pomaže u snižavanju razina glukoze u krvi, koje su zbog šećerne bolesti tipa 2 previsoke.
English: It is important that you continue with your diet and exercise plan as recommended by your doctor, pharmacist or nurse.
Croatian: Važno je nastaviti s režimom prehrane i tjelovježbom prema preporukama koje ste dobili od Vašeg liječnika, ljekarnika ili medicinske sestre.
English: Contact your doctor immediately if you notice any of the following side effects:
Croatian: Odmah se obratite liječniku ako primijetite bilo koju od sljedećih nuspojava:
English: At exposures sufficiently in excess of exposure in humans after therapeutic doses, the combination of empagliflozin and linagliptin was not teratogenic and did not show maternal toxicity.
Croatian: Pri izloženostima koje su bile dostatno više od izloženosti u ljudi nakon terapijskih doza, kombinacija empagliflozina i linagliptina nije bila teratogena i nije pokazivala toksičnost za majku.
English: • if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat.
Croatian: • ako iskusite nagli gubitak tjelesne težine, osjećaj mučnine ili povraćanje, bol u trbuhu, prekomjernu žeđ, ubrzano i duboko disanje, smetenost, neuobičajenu pospanost ili umor, zadah slatkog mirisa, slatki ili metalni okus u ustima, ili drugačiji miris mokraće ili znoja.